# Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells

> **NIH NIH R01** · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · 2020 · $991,540

## Abstract

ABSTRACT
Antibiotic resistance has become a significant public health threat. To combat the problem, a rapid pathogen
identification (ID) and antimicrobial susceptibility testing (AST) technology is needed to provide timely diagno-
sis of resistant infections and delivery of accurate antibiotic treatment at primary health-care settings, includ-
ing hospitals and point-of-care (POC). The present project aims to develop a point-of-care AST (POCASTTM)
technology based on a large-image-volume microscopy technique that enables direct detection of individual
bacterial cells in clinical samples without culturing or pathogen isolation, and a machine-learning model that
allows fast determination of pathogen and susceptibility. To establish the technology, the project will focus on
urinary tract infections (UTIs). UTIs affect millions of people annually, and the pathogens that usually cause
UTIs are the organisms that pose the highest threat of antimicrobial resistance, including carbapenem-
resistant Enterobacteriaceae (CRE) and extended spectrum β-lactamase (ESBL)-producing Enterobacteri-
aceae.
This project will focus on: 1) developing the large-image-volume microscopy and machine learning model for
simultaneous tracking of multi-phenotypic features of single bacterial cells directly in patient urine sample, and
performing rapid automatic pathogen ID and AST for UTIs; 2) building prototype instrument, and 3) validating
the instrument for UTIs using large scale clinical samples. Successful development and validation of the tech-
nology will enable precise antibiotic prescription on the same day of patient visit.
The project will be carried out by a multidisciplinary team with expertise in biosensors (Biodesign Center for
Bioelectronics and Biosensors, ASU), microbiology and infectious diseases (Biodesign Center for Immuno-
therapy, Vaccines and Virotherapy, ASU), biomedical instrument development and production (Biosensing
Instrument Inc.), and clinical testing (Clinical Microbiology Laboratory, Mayo Clinic).
!

## Key facts

- **NIH application ID:** 9970170
- **Project number:** 5R01AI138993-03
- **Recipient organization:** ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
- **Principal Investigator:** SHAOPENG WANG
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $991,540
- **Award type:** 5
- **Project period:** 2018-07-25 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9970170

## Citation

> US National Institutes of Health, RePORTER application 9970170, Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells (5R01AI138993-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9970170. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*